Moderna's Melanoma Vaccine Cuts Cancer Return Risk

After years of setbacks, Moderna just announced results that could change cancer treatment forever.

The Cambridge biotech company and partner Merck revealed their experimental melanoma vaccine reduced the chance of cancer returning or spreading in over 1,000 patients who had tumors surgically removed. The news sent Moderna's stock soaring and gave scientists renewed hope in a field that's struggled for five decades.

Dr. Patrick Ott, an oncologist at Dana Farber Cancer Institute, called the results "remarkable news." He's been waiting years for a study this large to confirm what his pioneering 2017 research suggested was possible.

The vaccine works by training your immune system to recognize and destroy cancer cells. Cancer develops when genes mutate and create special proteins called neoantigens. The mRNA vaccine teaches your body to spot these proteins as threats and eliminate them.

What makes this treatment special is that it's completely personalized. Doctors create a fresh vaccine for every single patient, tailored to their specific cancer's genetic signature. Combined with Keytruda, a drug that boosts immune response, the vaccine outperformed Keytruda alone.

Dr. Ryan Sullivan, who directs the cutaneous medical oncology program at Mass General Brigham Cancer Institute, has tested the drug on his own patients through all three trial phases. His verdict? "The fact that it's been shown to be effective? It's a no-brainer."

The Ripple Effect

This melanoma vaccine is just the beginning. Moderna and Merck are already running more than 10 additional studies testing the approach on lung cancer, bladder cancer, and other types.

The COVID pandemic actually accelerated this breakthrough. Scientists originally developed mRNA technology for cancer before adapting it for COVID vaccines. The pandemic forced companies to perfect the manufacturing process and prove they could produce mRNA vaccines quickly and at scale.

That means personalized cancer vaccines might be more affordable than you'd think. Compared to other cancer treatments, vaccines are relatively straightforward to produce.

Full trial results haven't been released yet, and some scientists remain cautious. Moderna plans to present complete data at an upcoming medical conference. But if the results hold up, both doctors say they would absolutely prescribe the treatment to their patients.

Sullivan sees this moment as potentially transformative. "If this leads to a reinvestment and reinvigoration of modern cancer vaccine development, that can help countless patients in different scenarios that we can't even think of right now."

After riding the bottom of the rollercoaster for 20 years, cancer vaccine research is finally climbing toward the top.